A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder

• Published in: Disease markers 2018-01, Vol.2018 (2018), p.1-6
• Main Authors: Saito, Kenkichi, Tanda, Naoki, Minami, Koichiro, Hirano, Hajime, Nomi, Hayahito, Kato, Ryuji, Hayashi, Tetsuya, Azuma, Haruhito, Uchimoto, Taizo, Takai, Tomoaki, Takahara, Kiyoshi, Komura, Kazumasa, Ibuki, Naokazu, Akao, Yukihiro, Uehara, Hirofumi, Inamoto, Teruo, Yoshikawa, Yuki
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Bladder; Bladder cancer; Cancer; Cancer therapies; Carcinoma; Carcinoma - genetics; Carcinoma - metabolism; Carcinoma - pathology; Chemotherapy; Deregulation; Genetic aspects; Genomes; Genomics; Humans; HyperText Markup Language; Male; Medical prognosis; Medical research; Medicine; Medicine, Experimental; Metastasis; MicroRNA; MicroRNAs; MicroRNAs - genetics; MicroRNAs - metabolism; miRNA; Patient outcomes; Patients; Phenotypes; Prognosis; Rank tests; Ribonucleic acid; Risk; RNA; Servers; Survival; Survival Analysis; Systematic review; Transcriptome; Urinary Bladder Neoplasms - genetics; Urinary Bladder Neoplasms - metabolism; Urinary Bladder Neoplasms - pathology; Urothelial carcinoma; Urothelium - metabolism; Urothelium - pathology; Web portals
• ISSN: 0278-0240; 1875-8630
• DOI: 10.1155/2018/5468672

Introduction and Objectives. MicroRNA (miRNA) expression is altered in urologic malignancies, including urothelial carcinoma of the bladder (UCB). Individual miRNAs have been shown to modulate multiple signaling pathways that contribute to BC. To identify a panel of miRNA signature that can predict aggressive phenotype from normal nonaggressive counterpart using miRNA expression levels and to assess the prognostic value of this specific miRNA markers in patients with UCB. Methods. To determine candidate miRNAs as prognostic biomarkers for dividing aggressive type of UCB, miRNA expression was profiled in patients’ samples with an aggressive phenotype or nonaggressive phenotype using 3D-Gene miRNA labeling kit (Toray, Japan). To create a prognostic index model, we used the panel of 9-miRNA signature based on Cancer Genome Atlas (TCGA) data portal (TCGA Data Portal (https://tcgadata.nci.nih.gov/tcga/tcgaHome2.jsp)). miRNA expression data and corresponding clinical data, including outcome and staging information of 84 UCB patients, were obtained. The Kaplan-Meier and log-rank test were performed to quantify the survival functions in two groups. Results. Deregulation of nine miRNAs (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-145-5p, hsa-miR-4324, hsa-miR-34b-5p, hsa-miR-29c-3p, hsa-miR-135a-3p, and hsa-miR-33b-3p) was determined in UCB patients with aggressive phenotype compared with nonaggressive subject. To validate the prognostic power of the nine-signature miRNAs using the TCGA dataset of bladder cancer, the survival status and tumor miRNA expression of all 84 TCGA UCB patients were ranked according to the prognostic score values. Of nine miRNAs, six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p). Patients with the high-risk miRNA signature exhibited poorer OS than patients expressing the low-risk miRNA profile (HR = 7.05, p